Shares of health-care companies rose amid deal activity. Fresenius' minority-owned kidney dialysis business agreed to buy smaller rival NxStage Medical for about $2 billion. The NxStage deal comes less than five months after Fresenius SE, which owns 31% of Fresenius Medical Care, agreed to buy U.S. generics drug manufacturer Akorn for $4.3 billion. Zynerba Pharmaceuticals plunged after the biotech company said an epilepsy product showed failed to bring about statistically significant improvements for sufferers in a mid-stage clinical trial.
-Rob Curran, firstname.lastname@example.org
Continue Reading Below
(END) Dow Jones Newswires
August 07, 2017 16:26 ET (20:26 GMT)